Загрузка...
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In th...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology
2004
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC400571/ https://ncbi.nlm.nih.gov/pubmed/15105105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.5.1553-1560.2004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|